A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children
A Phase 1 Study of EPZ-6438 (an EZH2 Inhibitor) in Pediatric Patients with Relapsed/Refractory INI1-Negative Tumors or Synovial Sarcomas
A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children
T2015-001 A phase I study of Inotuzumab Ozogamycin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are recurrent or refractory to standard therapy
A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adolescent patients with ≥2nd relapsed precursor B or T ALL